Agios PharmaceuticalsAGIO
Market Cap: $2.46B
About: Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Employees: 386
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
69% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 29
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
35% more capital invested
Capital invested by funds: $1.78B [Q1] → $2.41B (+$629M) [Q2]
11% more funds holding
Funds holding: 183 [Q1] → 203 (+20) [Q2]
6% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $11.8M
9.96% less ownership
Funds ownership: 108.4% [Q1] → 98.44% (-9.96%) [Q2]
38% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 80
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
RBC Capital Gregory Renza 45% 1-year accuracy 32 / 71 met price target | 27%upside $55 | Outperform Maintained | 2 Aug 2024 |
JP Morgan Tessa Romero 22% 1-year accuracy 4 / 18 met price target | 6%upside $46 | Neutral Reinstated | 13 Jun 2024 |